Pfizer Names Chief Operating Officer; Makes Other Senior Appointments
By

Pfizer has appointed Albert Bourla to the newly created position of chief operating officer, effective January 1, 2018.    

Bourla has been the Group President of Pfizer’s Innovative Health Business since the beginning of 2016. Prior to his current position, Bourla was the Group President for Pfizer’s Vaccines, Oncology, and Consumer Healthcare businesses. 

Over the course of his career, Bourla has held multiple senior global positions across a range of businesses and geographies. As general manager of the company’s Established Products Business Unit, he advanced the company’s efforts to build a strong post-patent business. Prior to leading the Established Products business, Bourla was the Area President for Pfizer’s Animal Health business across Europe, Africa, and Asia Pacific, where he managed the integration of Wyeth’s Animal Health Business (Fort Dodge) with Pfizer in these markets.

Effective January 1, 2018 John Young, group president, Pfizer Essential Health, becomes group president, Pfizer Innovative Health.  Angela Hwang, global president and general manager for Pfizer Inflammation & Immunology, will succeed Young as group president, Pfizer Essential Health. 

Young has held a number of senior leadership positions across Pfizer, including as president of the company’s Primary Care Business.  He is a scientist by training and has led the commercial and clinical development of medicines in key therapeutic areas, including cardiovascular disease, diabetes, and pain.

Hwang joined the company in 1997 in the company’s Corporate Strategic Planning and Policy Group. Her experience includes leadership roles within the Innovative Health and Essential health businesses as global president of Pfizer Inflammation and Immunology, regional head for US Vaccines, vice president of Emerging Markets for the Primary Care business, and vice president of the US Brands business within Essential Health. In her current role, she has been responsible for the growth of products such as Xeljanz (tofacitinib) and Eucrisa (crisaborole) and building a pipeline around rheumatology, gastroenterology, and dermatology.

Source: Pfizer

Leave a Reply

Your email address will not be published.